Top

Breast Cancer Research and Treatment

Published in:

01-06-2020 | Breast Cancer | Epidemiology

Financial toxicity and its associated patient and cancer factors among women with breast cancer: a single-center analysis of low-middle income region in China

Authors: Jingfeng Jing, Ran Feng, Xiaojun Zhang, Ming Li, Jinnan Gao

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Abstract

Purpose

To assess the financial toxicity (FT) and to investigate patients and cancer characteristic that associated with it in patients admitted in a tertiary hospital in central China.

Methods

This was a cross-sectional study of 166 patients from 188 with stage 0-III women breast cancer admitted in Bethune hospital in Taiyuan, Shanxi province during January–May 2019. FT was self-reported using of financial Toxicity Comprehensive Rating Scale (COST-FACIT). Patients’ sociodemographic factors, clinical examination, and cancer treatment were collected from questionnaire and hospital record. The financial concern and coping strategy was self-reported. Factors associated with FT were identified using linear regression analysis.

Results

Of the 166 completed the survey, the COST score ranged 0–40 with a mean of 21.2 (median 22.5, standard deviation 8.1). On multivariate linear regression analysis, older age (β coefficient: 0.20, 95% CI 0.11–0.29, p < 0.001), higher household income (β coefficient: 3000–5000 Yuan: 7.88, 95% CI 4.74–11.01, p < 0.001; ≥ 5000 Yuan: 12.81, 95% CI 9.54–16.08, p < 0.001) were positively associated with COST scores. Advanced cancer stage was the strongest predictor of FT among the cancer characteristics (β coefficient: − 4.52, 95% CI − 7.13–1.92, p = 0.001). To cope with the FT, 131 (78.8%) patients decreased non-medical expenses, and 56 (33.7%) reduced or quitted treatment.

Conclusions

FT was significantly associated with patient’s age, income, and cancer stage. Women having financial concerns after diagnosis were more likely to reduce their non-medical expenses and even quit treatments. Clinicians should take into account the FT levels in all patients and work out appropriate treatment strategies for optimal clinical outcome.

Available only for authorised users

Gordon LG, Merollini KMD, Lowe A, Chan RJ (2017) A systematic review of financial toxicity among cancer survivors: we can't pay the co-pay. Patient 10(3):295–309. https://doi.org/10.1007/s40271-016-0204-x CrossRefPubMed

Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, Newcomb P, Hollingworth W, Overstreet K (2013) Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 32(6):1143–1152. https://doi.org/10.1377/hlthaff.2012.1263 CrossRef

Kale HP, Carroll NV (2016) Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer 122(8):283–289. https://doi.org/10.1002/cncr.29808 CrossRefPubMed

Xia J, Tang Z, Deng QL, Yang RR, Wang JW, Yu JM (2018) Predictors of the quality of life in Chinese breast cancer survivors. Breast Cancer Res Tr 167(2):537–545. https://doi.org/10.1007/s10549-017-4512-1 CrossRef

Chan RJ, Gordon L, Zafar SY, Miaskowski C (2018) Financial toxicity and symptom burden: what is the big deal? Support Care Cancer 26(5):1357–1359. https://doi.org/10.1007/s00520-018-4092-6 CrossRefPubMed

Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, Newcomb P (2016) Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. J Clin Oncol 34(9):980–986. https://doi.org/10.1200/JCO.2015.64.6620 CrossRefPubMedPubMedCentral

Jagsi R, Pottow JA, Griffith KA, Bradley C, Hamilton AS, Graff J, Katz SJ, Hawley ST (2014) Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol 32(12):1269–1276. https://doi.org/10.1200/JCO.2013.53.0956 CrossRefPubMedPubMedCentral

Carrera PM, Kantarjian HM, Blinder VS (2018) The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 68(2):153–165. https://doi.org/10.3322/caac.21443 CrossRefPubMedPubMedCentral

Rosenzweig M, West M, Matthews J, Stokan M, Yoojin Kook YK, Gallups S, Diergaarde B (2019) Financial toxicity among women with metastatic breast cancer. Oncol Nurs Forum 46(1):83–91PubMed

10.

Voit A, Cross RK, Bellavance E, Bafford AC (2019) Financial toxicity in Crohn's disease. J Clin Gastroenterol 53(10):e438–e443. https://doi.org/10.1097/MCG.0000000000001139 CrossRefPubMed

11.

Honda K, Gyawali B, Ando M, Kumanishi R, Kato K, Sugiyama K, Mitani S, Masuishi T, Narita Y, Bando H, Taniguchi H, Kadowaki S, Ura T, Muro K (2019) Prospective survey of financial toxicity measured by the comprehensive score for financial toxicity in Japanese patients with cancer. J Glob Oncol 5:1–8. https://doi.org/10.1200/JGO.19.00003 CrossRefPubMed

12.

Huntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, Doshi JA, Stadtmauer EA (2015) Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol 2(10):e408–416. https://doi.org/10.1016/S2352-3026(15)00151-9 CrossRefPubMed

13.

The National Healthcare Security Administration (2019) Statistical Bulletin on the Development of National Basic Healthcarel Security in 2018. https://www.nhsa.gov.cn/art/2019/6/30/art_7_1477.html. Accessed 30 July 2019

14.

Liao XZ, Shi JF, Liu JS, Huang HY, Guo LW, Zhu XY, Xiao HF, Wang L, Bai YN, Liu GX, Mao AY, Ren JS, Sun XJ, Mai L, Liu YQ, Song BB, Gong JY, Zhou JY, Du LB, Zhou Q, Cao R, Zhu L, Ren Y, Lou PA, Lan L, Sun XH, Qi X, Wang YZ, Zhang K, He J, Dai M (2018) Medical and non-medical expenditure for breast cancer diagnosis and treatment in China: a multicenter cross-sectional study. Asia Pac J Clin Oncol 14(3):167–178. https://doi.org/10.1111/ajco.12703 CrossRefPubMed

15.

Zheng Z, Yabroff KR, Guy GP Jr et al (2015) Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv382 CrossRefPubMedPubMedCentral

16.

Su M, Zhang N, Cai Y, Wang J, Anderson R, Yao N, Sun X (2019) Work and income changes after cancer in rural China: a cross-sectional survey. Cancer Med. https://doi.org/10.1002/cam4.2627 CrossRefPubMedPubMedCentral

17.

Hakanen JJ, Lindbohm ML (2008) Work engagement among breast cancer survivors and the referents: the importance of optimism and social resources at work. J Cancer Surviv 2(4):283–295. https://doi.org/10.1007/s11764-008-0071-0 CrossRefPubMed

18.

Fantoni SQ, Peugniez C, Duhamel A, Skrzypczak J, Frimat P, Leroyer A (2010) Factors related to return to work by women with breast cancer in northern France. J Occup Rehabil 20(1):49–58. https://doi.org/10.1007/s10926-009-9215-y CrossRefPubMed

19.

Hassett MJ, O'Malley AJ, Keating NL (2009) Factors influencing changes in employment among women with newly diagnosed breast cancer. Cancer 115(12):2775–2782. https://doi.org/10.1002/cncr.24301 CrossRefPubMed

20.

de Souza JA, Yap BJ, Hlubocky FJ, Wroblewski K, Ratain MJ, Cella D, Daugherty CK (2014) The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer 120(20):3245–3253. https://doi.org/10.1002/cncr.28814 CrossRefPubMed

21.

de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araujo FS, Hlubocky FJ, Nicholas LH, O'Connor JM, Brockstein B, Ratain MJ, Daugherty CK, Cella D (2017) Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer 123(3):476–484. https://doi.org/10.1002/cncr.30369 CrossRefPubMed

22.

Yu HH, Bi X, Liu YY (2017) Reliability and validity of the Chinese version on Comprehensive Scores for Financial Toxicity based on the patient-reported outcome measures. Zhonghua Liu Xing Bing Xue Za Zhi 38(8):1118–1120. https://doi.org/10.3760/cma.j.issn.0254-6450.2017.08.024 CrossRefPubMed

23.

Shanxi Statistical Yearbook 2018 (2019) Per Captia Income and Expenditure of Resident Household by income. (2018).https://tjj.shanxi.gov.cn/tjsj/tjnj/nj2018/indexch.htm?from=singlemessage&isappinstalled. Accessed 12 July 2019

24.

Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 69(5):363–385. https://doi.org/10.3322/caac.21565 CrossRefPubMed

25.

Schoen C, Doty MM, Robertson RH, Collins SR (2011) Affordable Care Act reforms could reduce the number of underinsured US adults by 70 percent. Health Aff (Millwood) 30(9):1762–1771. https://doi.org/10.1377/hlthaff.2011.0335 CrossRef

26.

Aranda S, Currow D (2016) Financial toxicity in clinical care today: a "menu without prices". Med J Aust 205(11):529–530. https://doi.org/10.5694/mja16.00960 CrossRefPubMed

27.

Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso MJ, Dent RA, Gelmon K, Gentilini O, Harbeck N, Margulies A, Meirow D, Pruneri G, Senkus E, Spanic T, Sutliff M, Travado L, Peccatori F, Cardoso F (2017) ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast 35:203–217. https://doi.org/10.1016/j.breast.2017.07.017 CrossRefPubMed

28.

Lentz R, Benson AB 3rd, Kircher S (2019) Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies. J Surg Oncol 120(1):85–92. https://doi.org/10.1002/jso.25374 CrossRefPubMed

29.

Grouw AS, Kimman M, Jan S, Yip CH, Thabrany H, Peters SA, Bhoo-Pathy N, Woodward M (2015) Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: results from a longitudinal study in eight countries. BMC Med 13:190. https://doi.org/10.1186/s12916-015-0433-1 CrossRef

30.

O'Donnell O, van Doorslaer E, Rannan-Eliya RP, Somanathan A, Adhikari SR, Akkazieva B, Harbianto D, Garg CC, Hanvoravongchai P, Herrin AN, Huq MN, Ibragimova S, Karan A, Kwon SM, Leung GM, Lu JF, Ohkusa Y, Pande BR, Racelis R, Tin K, Tisayaticom K, Trisnantoro L, Wan Q, Yang BM, Zhao Y (2008) Who pays for health care in Asia? J Health Econ 27(2):460–475. https://doi.org/10.1016/j.jhealeco.2007.08.005 CrossRefPubMed

31.

Zheng A, Duan W, Zhang L, Bao X, Mao X, Luo Z, Jin F (2018) How great is current curative expenditure and catastrophic health expenditure among patients with cancer in China? A research based on "System of Health Account 2011". Cancer Med 7(8):4036–4043. https://doi.org/10.1002/cam4.1590 CrossRefPubMedPubMedCentral

32.

Huang HY, Shi JF, Guo LW (2016) Expenditure and financial burden for common cancers in China: a hospital-based multicenter cross-sectional study. Lancet 388:S10. https://doi.org/10.1016/S0140-6736(16)31937-7 CrossRef

33.

Islam T, Dahlui M, Majid HA, Nahar AM, Mohd Taib NA, Su TT, My BCCsg (2014) Factors associated with return to work of breast cancer survivors: a systematic review. BMC Public Health 14(Suppl 3):S8. https://doi.org/10.1186/1471-2458-14-S3-S8 CrossRefPubMedPubMedCentral

34.

DiSipio T, Rye S, Newman B, Hayes S (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500–515. https://doi.org/10.1016/S1470-2045(13)70076-7 CrossRefPubMed

35.

Dean LT, Moss SL, Ransome Y, Frasso-Jaramillo L, Zhang Y, Visvanathan K, Nicholas LH, Schmitz KH (2019) "It still affects our economic situation": long-term economic burden of breast cancer and lymphedema. Support Care Cancer 27(5):1697–1708. https://doi.org/10.1007/s00520-018-4418-4 CrossRefPubMed

36.

Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, Abernethy AP (2013) The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18(4):381–390. https://doi.org/10.1634/theoncologist.2012-0279 CrossRefPubMedPubMedCentral

37.

Perez EA, Romond EH, Suman VJ et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor-2 positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744–3752. https://doi.org/10.1200/JCO.2014.55.5730 CrossRefPubMedPubMedCentral

38.

Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL, American Society of Clinical O (2015) American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33(23):2563–2577. https://doi.org/10.1200/JCO.2015.61.6706 CrossRefPubMedPubMedCentral

Title: Financial toxicity and its associated patient and cancer factors among women with breast cancer: a single-center analysis of low-middle income region in China
Authors: Jingfeng Jing
Ran Feng
Xiaojun Zhang
Ming Li
Jinnan Gao
Publication date: 01-06-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05632-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning

Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB)

Evaluation and management of insomnia in women with breast cancer

Carbon ion radiation therapy in breast cancer: a new frontier

Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis

Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer